Microbot Medical Inc. (MBOT)
| Market Cap | 124.91M +24.4% |
| Revenue (ttm) | 105,000 |
| Net Income | -14.21M |
| EPS | -0.26 |
| Shares Out | 67.16M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,061,515 |
| Open | 1.880 |
| Previous Close | 1.880 |
| Day's Range | 1.810 - 1.910 |
| 52-Week Range | 1.600 - 4.670 |
| Beta | 1.03 |
| Analysts | Strong Buy |
| Price Target | 7.00 (+276.34%) |
| Earnings Date | May 13, 2026 |
About MBOT
Microbot Medical Inc. is a medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system designed to maneuver guidewires and over-the-wire devices such as microcatheters within the body’s vasculature for use in cardiovascular, peripheral, endovascular, and neurovascular operations. It also provides NovaCross, an intellectual property and technology in the field of intraluminal reva... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for MBOT stock is "Strong Buy." The 12-month stock price target is $7.0, which is an increase of 276.34% from the latest price.
News
Microbot Medical management to meet virtually with B. Riley
Virtual Meeting to be held on June 23 hosted by B. Riley.
Microbot enters federal healthcare systems pact with Lovell Government Services
Microbot Medical (MBOT) has entered into an agreement with Lovell Government Services to serve federal healthcare systems, such as those administered by the Veterans Health Administration, a division ...
Microbot Medical® Enters Into an Agreement to Expand Access for America's Veteran and Military Patient Populations
HINGHAM, Mass., June 16, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, has entered into an agreement ...
Microbot Medical® Announces a Notable Health System as the First in Michigan to Adopt the LIBERTY® Endovascular Robotic System
HINGHAM, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that one of the larg...
Microbot Medical initiated with a Buy at Lucid Capital
Lucid Capital analyst Alex Nowak initiated coverage of Microbot Medical (MBOT) with a Buy rating and $4 price target The company’s Liberty robot system is a “novel approach in a…
Microbot Medical® Secures the First Healthcare System in North Carolina to Adopt the LIBERTY® Endovascular Robotic System
HINGHAM, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that it has secured ...
Microbot Medical announces Israel granted marketing clearance for Liberty
Microbot Medical (MBOT) announced that it has achieved a significant regulatory milestone as Israel becomes the second jurisdiction – and the first outside of the U.S. – to grant marketing…
Microbot Medical® Receives Its First International Regulatory Approval for the Commercialization of the LIBERTY® Endovascular Robotic System
Israel becomes the second jurisdiction and the first outside of the U.S. to grant marketing clearance for the LIBERTY System The AMAR regulatory approval will enable the Company to obtain a Free Sale ...
Microbot Medical to Hold Analysts and Investors Conference Call to Review Recent Progress; Executive Team will be Joined by Current Users of the LIBERTY Endovascular Robotic System, Dr. Charles Briggs and Dr. Zachary Bercu
Microbot to Hold Conference Call to Review Recent Progress; Executive Team to be Joined by Current LIBERTY Users, Dr. Charles Briggs and Dr. Zachary Bercu
Microbot Medical Successfully Transitions to Commercial Operations as It Records Revenue Resulting from Its Limited Market Release During the First Quarter of 2026
Recent transition to the Full Market Release has already resulted in increased revenue for the current Q2, which has already exceeded Q1 revenue, as utilization and adoption of the LIBERTY System acce...
Microbot Medical Quarterly report: Q1 2026
Microbot Medical has published its Q1 2026 quarterly earnings report on May 13, 2026.
Microbot Medical®'s LIBERTY® Endovascular Robotic System is Now Adopted by Multiple Accounts Across Key Territories Including Two ACCESS-PVI Pivotal Clinical Trial Sites
Commercial adoption of the LIBERTY System by sites that participated in the clinical trial serves as a strong validation of the value it brings to everyday practice The Company will attend the Annual ...
Microbot Medical® Announces the Addition of Senior Commercial Executive with Proven Track Record to Accelerate Commercial Readiness in Europe, the Middle East, and Asia (EMEA)
Commencement of activities in international markets is supported by the successful completion of the Limited Market Release, followed by the Recent Full Market Release in the U.S. Strong physician in...
Microbot Medical® Welcomes Updated Occupational Protection Guidelines from Leading Medical Societies, Strengthening Commercial Position of LIBERTY®
Members of the Society of Interventional Radiology (SIR) and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Represent the Largest Addressable User Market for the LIBERTY ...
Microbot Medical® to Highlight Commercial Achievements Leading to the Full Market Release (FMR) of the LIBERTY® Endovascular Robotic System at the 25th Annual Needham Virtual Healthcare Conference
The presentation will be webcast live on April 15 at 10:15 a.m. ET. Continued Engagement with Healthcare Institutions Reflects Rising Momentum The presentation will be webcast live on April 15 at 10:1...
Microbot Medical begins full market release of LIBERTY endovascular system
Microbot Medical (MBOT) announced that it has successfully executed its limited market release and will commence the full market release of its LIBERTY endovascular robotic system in the U.S. as…
Microbot Medical® Commences Full Market Release (FMR) of the LIBERTY® Endovascular Robotic System in the U.S. at the Society of Interventional Radiology (SIR) Annual Scientific Meeting
HINGHAM, Mass., April 13, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced today that it has s...
Emory Healthcare Successfully Completes Robotic Peripheral Endovascular Procedures using Microbot Medical®'s LIBERTY® Endovascular Robotic System
World's first robotic Prostatic Artery Embolization (PAE) for Benign Prostatic Hyperplasia (BPH) and robotic Y-90 radioembolization mapping for liver cancer are among the robotic cases performed...
Microbot Medical Annual report: Q4 2025
Microbot Medical has published its Q4 2025 annual report on March 26, 2026.
Microbot Medical announces publication of ACCESS PVI pivotal study results
Microbot Medical (MBOT) announced the publication of an article in the Journal of Vascular and Interventional Radiology, titled “In Vivo Evaluation of a Disposable Endovascular Robotic System for Arte...
Microbot Medical® Strengthens LIBERTY® Endovascular Robotic System Position with Publication of its ACCESS PVI Pivotal Study in Leading Peer-Reviewed Medical Journal
Being Published in the Journal of Vascular and Interventional Radiology, a Premier Peer-Reviewed Journal, Speaks to the Quality and Impact of the Study Company Remains Focused on Expanding Evidence-Ba...
Microbot Medical® to Participate at the 38th Annual Roth Conference
HINGHAM, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that it will partic...
Microbot Medical® to Participate at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference for The First Time
HINGHAM, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that it will be par...
Microbot ‘commends’ AMA for efforts to protect workers from ionizing radiation
Microbot Medical (MBOT) “commends” the American Medical Association’s, AMA, expanding efforts to protect health care professionals from ionizing radiation. In late 2025, the AMA adopted a new policy t...
Microbot Medical® Aligns with Recently Adopted Policy of the Largest U.S.-Based Medical Association to Expand Protection for Healthcare Professionals from Ionizing Radiation
LIBERTY® Endovascular Robotic System's Capability to Reduce Radiation Exposure Appeals to Hospitals and Healthcare Providers LIBERTY® Endovascular Robotic System's Capability to Reduce Radiation Expos...